Search clinical trials for: OROS hydromorphone HCI (slow release)

Total 317 results

Alza Corporation, DE, USA

Completed

A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis

Osteoarthritis, Knee | Osteoarthritis, Hip
Alza Corporation, DE, USA

Completed

Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain

Pain
Alza Corporation, DE, USA

Completed

Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain

Low Back Pain
Alza Corporation, DE, USA

Completed

An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg

Analgesia
Alza Corporation, DE, USA

Completed

A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain

Low Back Pain
Janssen Korea, Ltd., Korea

Completed

Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid

Pain

Korea, Republic of
Alza Corporation, DE, USA

Completed

A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain

Pain | Analgesics | Opioid
Alza Corporation, DE, USA

Completed

A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain

Pain, Postoperative | Analgesia | Orthopedic Procedures
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer

Pain | Cancer
Janssen Pharmaceutica

Terminated

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

Pain
Janssen-Cilag International NV

Completed

Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee

Pain | Osteoarthritis, Knee | Osteoarthritis, Hip

United Kingdom, Romania, Slovakia, Czech Republic
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.

Pain

France, Poland, Germany, Slovenia, Sweden, Czech Republic, Norway, Slovakia, Switzerland, Denmark
Alza Corporation, DE, USA

Completed

An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)

Osteoarthritis, Knee | Osteoarthritis, Hip
Alza Corporation, DE, USA

Completed

A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.

Pain | Analgesics, Opioid
Johnson & Johnson Taiwan Ltd

Terminated

A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain

Cancer Pain
Janssen Korea, Ltd., Korea

Completed

Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients

Cancer Pain

Korea, Republic of
Mallinckrodt

Completed

A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain

Chronic Pain
Janssen Korea, Ltd., Korea

Completed

An Observational Study to Investigate Clinical Usefulness of OROS Hydromorphone in Korean Cancer Patients

Pain
Mallinckrodt

Completed

Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain

Chronic Low Back Pain
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
University of Aarhus
Innovation Fund Denmark

Recruiting

The Effect of Alginate Encapsulated Supplements on Athletic Performance and Recovery (SWAP)

Athletic Performance

Denmark
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Shirley Ryan AbilityLab
Mallinckrodt

Completed

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain (Covidien)

Low Back Pain

United States
Purdue Pharma LP

Terminated

Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

Chronic Non-Malignant Pain

United States
Janssen-Cilag International NV

Completed

A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit/ Hyperactivity Disorder

France, Belgium, Germany, Spain, Switzerland, Denmark, Finland, Netherlands, Norway, Sweden, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain

Pain

China
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Vishal Uppal

Completed

Pre-emptive Opioid Treatment to Prevent Rebound Pain After Arthroscopic Rotator Cuff Repair and/or Acromioplasty Under General Anesthesia and Interscalene Block

Pain | Rotator Cuff Injury

Canada
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Healthy
Mallinckrodt

Terminated

Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients

Chronic Pain

United States
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Fujian Cancer Hospital

Not yet recruiting

IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration

Cancer Pain

China
Medical University of Vienna
Reproductive Sciences Ltd.

Unknown

EVIE-Study: Slow Release Insemination Versus Standard Intrauterine Insemination Study (EVIE)

Insemination

Austria, France, Germany, United Kingdom
University of Tennessee

Active, not recruiting

Investigating Proximal Muscle Strength Effects by Incorporating Proximal Muscle Lengthening

Proximal Muscle Strength | Proximal Muscle Lengthening

United States
LG Life Sciences

Unknown

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.

Healthy

Korea, Republic of
Massachusetts General Hospital
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

Healthy

United States
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Second Affiliated Hospital, School of Medicine,...

Unknown

The Effect of Esketamine on Patients Undergoing Tumor Surgery

Tumor Surgery

China
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Evaluate Pharmacokinetics and Safety of Slow Release DHEA (DHEA)

Asthma | Genotype

United States
Mahidol University

Not yet recruiting

The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original

Adhd
Nova Scotia Health Authority
Canadian Institutes of Health Research (CIHR); Nova Scotia Health Research... and other collaborators

Completed

Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD) (ROS-003)

Chronic Obstructive Pulmonary Disease (COPD)

Canada
AUVA Traumazentrum Vienna Site UKH Meidling

Completed

Pain Management After Elective Shoulder Surgery

Postoperative Pain

Austria
Wuhan Union Hospital, China

Recruiting

Effect of APRV vs. LTV on Right Heart Function in ARDS Patients: a Single-center Randomized Controlled Study

Acute Respiratory Distress Syndrome | Mechanical Ventilation | Right Heart Failure

China

3

Subscribe